You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Neoadjuvant or Adjuvant Therapy for Resectable Gastric Cancer

Version: 3 ID: 2-14 avr 2011
Type of Content: Guidelines & Advice, Clinical
Document Status: Archived
Authors:
G. Knight, C.C. Earle, R. Cosby, N. Coburn, Y. Youssef, K. Spithoff, R. Malthaner, R.K.S. Wong, Gastrointestinal Cancer Disease Site Group

Patient Population

Adult patients with potentially curable, surgically resectable (Stage 1B [invasion of the muscularis propria] and above) gastric cancer.

Intended Guideline Users

Clinicians and healthcare providers involved in the management and referral of patients with resectable gastric cancer.

Research Question(s)

Should patients with resectable gastric cancer (Stage 1B [invasion of the muscularis propria] and above) receive neoadjuvant or adjuvant therapy in addition to surgery? Outcomes of interest are overall survival (OS), disease-free survival (DFS), and adverse events.